


| |||||||||||||||||
|
IMS’s mission is to help clients enhance the quality of healthcare throughout the world – so more people can live longer, healthier, more productive lives.
We are an objective, unbiased source of business intelligence for pharmaceutical and biotech companies … governments and public health institutions … drug safety and patient advocacy organizations … medical and academic researchers … healthcare regulatory agencies … and industry observers, including journalists and the financial community.
IMS information and expertise play a critical role in advancing healthcare research projects across the globe – from public policy studies that seek to allocate healthcare resources more equitably, to assessments of drug therapies and outcomes and patient trends and treatments. Some recent examples include a European Union Study on comparative antibiotic use; a U.N. World Health Organization initiative to deploy “orphan” drugs — less profitable drugs targeted at rare diseases, or at diseases of poverty in economically disadvantaged populations; a US study assessing the impact of parent and clinician education on pediatric prescribing behavior; and a Canadian program to enhance healthcare provider and community awareness of antibiotics for respiratory tract infections.
Responsible Corporate Citizens
The key ingredient in our success is our people, whose experience, expertise and commitment set the industry standard. IMS people live and work in more than 100 countries, where they reflect the diversity of our customers and support local charities with donations and volunteers.
We know that great companies adhere to strong ethical principles, and employees of great companies live by those principles, every day. That is why our commitment to integrity, honesty and ethical conduct is a business imperative as fundamental as the expertise we provide. Our policy on business conduct embodies the basic elements of decency, fairness and good judgment – principles woven into the fabric of everything we do: